Regulation of the Thrombotic Potential of Atheroma

Peter Libby; François Mach; Uwe Schönbeck; Todd Bourcier; Masanori Aikawa

doi:10.1055/s-0037-1615905

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1999; 82(02): 736-741
DOI: 10.1055/s-0037-1615905

Research Article

Schattauer GmbH

Regulation of the Thrombotic Potential of Atheroma

Peter Libby

¹Vascular Medicine and Atherosclerosis Unit, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

,

François Mach

¹Vascular Medicine and Atherosclerosis Unit, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

,

Uwe Schönbeck

¹Vascular Medicine and Atherosclerosis Unit, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

,

Todd Bourcier

¹Vascular Medicine and Atherosclerosis Unit, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

,

Masanori Aikawa

¹Vascular Medicine and Atherosclerosis Unit, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

› Author Affiliations

Abstract

Introduction

Thrombosis underlies most acute manifestations of atherosclerosis and likely is an important contributor to the evolution of atherosclerotic lesions. In the coronary arteries, thrombosis precipitates most episodes of unstable angina and acute myocardial infarction (both Q-wave and non Q- wave). But, of course, atherosclerosis is a systemic disease that affects many arterial beds. Thus, the thrombotic complications of atherosclerosis also cause many strokes and acute exacerbations of peripheral vascular disease that place limbs in jeopardy.

Many studies have clarified the microanatomy of fatal coronary thrombosis. Flow limiting stenoses were formerly considered the cause of the acute coronary syndromes. Recent clinical observations, however, have taught us that most myocardial infarctions result from thrombi that occur on the substrate of a lesion that does not cause a critical narrowing of a coronary artery. We now appreciate that a physical disruption of the atheromatous plaque most often provokes thrombus formation. Plaque disruption takes two major forms: a frank fissuring of the plaque’s fibrous cap and a superficial erosion of the intimal surface (Table 1). In the case of a ruptured cap, blood coagulation factors come into contact with the plaque’s lipid core, which is rich in tissue factor and considered the major procoagulant in this situation. In the case of superficial erosion, platelets can contact subendothelial basement membrane and collagen within the plaque, which may trigger platelet aggregation. Additionally, smooth muscle cells underlying the endothelium can also express tissue factor, further contributing to thrombus formation.

Excellent evidence suggests that plaque rupture occurs frequently, even in asymptomatic individuals. Consequently, most arterial thrombi do not produce clinical manifestations. Presumably, most mural thrombi either fail to occlude the vessel, as they do not propagate, or are evanescent. A healing mural thrombus, although clinically silent, may still contribute to plaque growth. Platelets contain potent fibrogenic mediators, such as platelet-derived growth factor (a smooth muscle cell chemoattractant) and transforming growth factor (TGF)-β (a strong stimulus to smooth muscle collagen gene expression). Thrombin and activated factor X can stimulate smooth muscle cell proliferation by direct and/or indirect routes. These mediators may link healing mural thrombi in arteries to intimal growth and the formation of stenotic lesions.

Why do some plaque disruptions lead to an occlusive thrombus that may cause sudden death, while other disruptions pass unnoticed? The locally prevailing hemostatic and fibrinolytic balance likely proves decisive in determining the fate of a given disruption of an atheroma. Much evidence has recently accumulated regarding the factors that regulate these regional balances. This chapter will selectively summarize certain of those recent findings. It will also provide some mechanistic insight into how contemporary therapies may act to reduce the thrombotic complications that cause the most dreaded and dramatic complications of atherosclerosis.

Full Text

References

References
1 Ross R. The pathogenesis of artheroselecrosis: a perspective for 1990s. Nature 1993; 362: 801-809.
2 Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-2850.
3 Fuster V. Mechanisms leading to myocardial infarction: Insights from vascular biology. Circulation 1994; 90: 2126-2146.
4 Annex BH, Denning SM, Channon KM, Sketch MH, Stack RS, Morrissey JH, Peters KG. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995; 91: 619-622.
5 van der Wal A C, Becker A E, van der Loos C M, Das P K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36-44.
6 Wilcox J N, Smith K M, Schwartz S M, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci. USA 1989; 86: 2839-2843.
7 Moreno P R, Bernardi V H, Lopez-Cuellar J, Murcia A M, Palacios I F, Gold H K, Mehran R, Sharma S K, Nemerson Y, Fuster V, Fallon J. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Circulation 1996; 94: 3090-3097.
8 Libby P, Ross R. Cytokines and growth regulatory molecules. In: Fuster V, Ross R, Topol E. eds Atherosclerosis and Coronary Artery Disease, Vol. 1. Lippincott-Raven; New York: 1996: 585-594.
9 Moreno P R, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90: 775-778.
10 Galis Z, Sukhova G, Lark M, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
11 Hansson GK, Jonasson L, Holm J, Clowes MK, Clowes A. Gamma interferon regulates vascular smooth muscle proliferation and Ia expression in vivo and in vitro. Circ Res 1988; 63: 712-719.
12 Zhou X, Stemme S, Hansson GK. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am J Pathol 1996; 149: 359-366.
13 Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991; 64: 5-15.
14 Hansson GK, Jonasson L, Seifert PA, Stemme S. Immune mechanisms in atherosclerosis. Arteriosclerosis 1989; 9: 567-578.
15 Fuster V, Badimon I, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Eng J Med 1992; 326: 242-250.
16 Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986; 6: 131-138.
17 Hansson GK. Cell-mediated immunity in atherosclerosis. Curr Opin Lipidol 1997; 8: 301-311.
18 Stemme S, Holm J, Hansson GK. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb 1992; 12: 206-211.
19 Gregory SA, Edgington TS. Tissue factor induction in human monocytes: two distinct mechanisms displayed by different alloantigen-responsive T cell clones. J Clin Invest 1985; 76: 2440-2445.
20 Mach F, Schönbeck U, Sukhova GK, Bourcier T, Bonnefoy J-Y, Pober JS, Libby P. Functional CD 40 Ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA. 1997; 94: 1931-1936.
21 Laman JD, de Smet BJ, Schoneveld A, van Meurs M. CD40-CD40L interactions in atherosclerosis. Immunol Today 1997; 18: 272-277.
22 Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 199614: 591-617.
23 Clark LB, Foy TM, Noelle RJ. CD40 and its ligand. Adv Immunol 1996; 63: 43-78.
24 Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L. Identification of a novel surface protein on activated CD4⁺ T cells that induces contact-dependent B cells differentiation. J Exp Med 1992; 175: 1091-1101.
25 Yellin MJ, Brett J, Baum D, Matsushima A, Szablocs M, Stern D, Chess L. Functional interactions of T cells with endothelial cells: The role of CD40L-CD40-mediated signals. J Exp Med 1995; 182: 1857-1864.
26 Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 1995; 92: 4342-346.
27 Hollenbaugh D, Mischel-Petty N, Edwards CP, Simons JC, Denfeld RW, Kiener PA, Aruffo A. Expression of functional CD40 by vascular endothelial cells. J Exp Med 1995; 182: 33-40.
28 Malik N, Greenfield BW, Wahl AF, Kiener PA. Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol 1996; 156: 3952-3960.
29 Mach F, Schönbeck U, Fabumni RP, Murphy C, Bonnefoy J-Y, Libby P. Activation of endothelial cells by interaction with T cells induces matrix metalloproteinases through CD40L-CD40 signals: implications for the pathogenesis of atherosclerosis. Am J Pathol 1999; 1: 1-9.
30 Mach F, Schönbeck U, Bonnefoy J-Y, Pober JS, Libby P. Activation of monocyte/macrophage function related to acute atheromata complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997; 96: 396-399.
31 Schönbeck U, Herzberg M, Petersen A, Wohlenberg C, Gerdes J, Flad H-D, Loppnow H. Human vascular smooth muscle cells express interleukin-1ß-converting enzyme (ICE), but inhibit processing of the interleukin-1ß precursor by ICE. J Exp Med 1997; 185: 1287-1294.
32 Schönbeck U, Mach F, Sukhova GK, Atkinson E, Levesque E, Herman M, Graber P, Basset P, Libby P. Expression of Stromelysin-3 in atherosclerotic lesions. J Exp Med 1999; 189: 1-11.
33 Mach F, Schönbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in a mouse model by interruption of CD40-CD40L signaling. Nature 1998; 394: 200-203.
34 Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-3124.
35 Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-1072.
36 Loskutoff DJ, van Mourik JA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 1983; 80: 2956-2960.
37 Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor-1 and atherothrombosis. Thromb Haemost 1993; 71: 138-143.
38 Krishnamurti C, Alving BM. Plasminogen activator inhibitor type 1: biochemistry and evidence for modulation of fibrinolysis in vivo. Semin Thromb Hemost 1992; 18: 67-80.
39 Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
40 Robbie LA, Booth NA, Brown PAJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1996; 16: 539-545.
41 Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol 1998; 18: 1-6.
42 Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988; 70: 327-333.
43 Gallicchio M, Hufnagl P, Wojta J, Tipping P. IFN-gamma inhibits thrombin- and endotoxin-induced plasminogen activator inhibitor type 1 in human endothelial cells. J Immunol 1996; 157: 2610-2617.
44 Xiao Q, Danton MJ, Witte DP, Kowala MC, Valentine MT, Bugge TH, Degen JL. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 10335-10340.
45 4S Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
46 Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
47 Libby P, Geng YJ, Aikawa M, Schoenbeck U, Mach F, Clinton SK, Sukhova GK, Lee RT. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 1996; 7: 330-335.
48 Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brinckerhoff CE, Sukhova GK, Libby P. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998; 97: 2433-2444.
49 Aikawa M, Rabkin E, Voglic SJ, Shing H, Nagai R, Schoen FJ, Libby P. Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain iso-forms in rabbit atheroma. Circ Res 1998; 83: 1015-1026.
50 Aikawa M, Voglic SJ, Sugiyama S, Rabkin E, Taubman MB, Fallon JT, Libby P. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation. In press.
51 Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, Fallon JT. In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest 1996; 75: 451-461.
52 Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
53 Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto Jr AM. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
54 Aikawa M, Voglic SJ, Rabkin E, Shiomi M, Libby P. An HMG-CoA reductase inhibitor (cerivastatin) suppresses accumulation of macrophages expressing matrix metalloproteinases and tissue factor in atheroma of WHHL rabbits. Circulation 1998; 98: I-47.
55 Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages: A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997; 17: 265-272.
56 Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, Fumagalli R, Paoletti R, Corsini A. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1996; 137 Suppl S101-109.
57 Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279: 1643-1650.
58 Essig M, Vrtovsnik F, Nguyen G, Sraer JD, Friedlander G. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins. J Am Soc Nephrol 1998; 9: 1377-1388.
59 Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279: 509-514.
60 Gelb MH, Scholten JD, Sebolt-Leopold JS. Protein prenylation: from discovery to prospects for cancer treatment. Curr Opin Chem Biol 1998; 2: 40-48.